2004-239 – Mayo Clinic has patent rights claiming the use of PD1 and PD-L1 antibodies to treat cancer. The patent rights also include diagnostic and prognostic claims.
2012-073 – Erectile dysfunction (ED) is estimated to affect 20-30% of men between the ages of 40-80 years. In cases of medication-resistant ED, surgical treatment, and especially penile prosthesis implantation is the standard of care. Complications of surgery can include neurovascular and urethral injury, and other tissue damage that can contribute to sub-optimal outcomes. A Mayo Clinic investigator... Read More
2011-271 – We identified a novel translocation of TP63 gene which encodes p63 protein. The translocation leads to overexpression of a dominant negative TP63 isoform. Dominant negative TP63 isoforms lead to inactivation of p53, the most important tumor suppressor known. The translocation can be useful for diagnosis and subclassification of certain peripheral T cell lymphomas, B-cell lymphomas... Read More
2011-245 – Immune responses directed toward many cancers are characterized by targeted cell-killing activities mediated by cytotoxic T cells (a.k.a. Thl responses). However, certain tumors such as bladder cancer, instead appear to elicit immune responses that are traditionally linked with allergies (a.k.a. Th2 responses). These immune responses also include the tissue recruitment of rare white blood... Read More
2010-316 – Technology Description C-type natriuretic peptide (CNP) is a 22 amino acid peptide which is primarily produced by endothelial cells and possesses potent antifibrotic and antiproliferative properties. Mayo Clinic researchers have shown that elevated levels of CNP in the urine correlate with renal fibrosis and decline in renal function. In congestive heart failure patients, urinary CNP... Read More
2006-018 – Technology Description B7-H4 is a cell surface protein whose expression on tumor cells and tumor-associated vasculature is greatly increased in renal cancers. B7-H4 expression levels on renal tumors have been shown to be a predictor of tumor aggressiveness and to increase mortality rates. B7-H4 is highly expressed on tumors and tumor-associated vasculature but not on normal tissues and... Read More